Cargando…

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study

BACKGROUND AND HYPOTHESES: Weight gain and adverse cardiometabolic effects often limit the clinical utility of olanzapine. In ENLIGHTEN-2, combining olanzapine with the opioid receptor antagonist samidorphan (OLZ/SAM) mitigated olanzapine-associated weight gain. These analyses tested the hypothesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correll, Christoph U, Stein, Evan, Graham, Christine, DiPetrillo, Lauren, Akerman, Sarah, Stanford, Arielle D, Jiang, Ying, Yagoda, Sergey, McDonnell, David, Hopkinson, Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016392/ https://www.ncbi.nlm.nih.gov/pubmed/36305696 http://dx.doi.org/10.1093/schbul/sbac144

Ejemplares similares

Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
por: Sun, Lei, et al.
Publicado: (2019)

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
por: Sun, Lei, et al.
Publicado: (2019)

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Srisurapanont, Manit, et al.
Publicado: (2021)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
por: Peng, Zhenlei, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Comment on “Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review”
por: Todtenkopf, Mark S., et al.
Publicado: (2023)

Using physiologically‐based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet
por: Sun, Lei, et al.
Publicado: (2021)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
por: Hill, Angela L, et al.
Publicado: (2011)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
por: Ciudad, Antonio, et al.
Publicado: (2013)

Pharmacovigilance on olanzapine
por: Lingeswaran, Anand, et al.
Publicado: (2010)

Teratogenicity with Olanzapine
por: Prakash, Sathya, et al.
Publicado: (2014)

Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
por: Correll, Christoph U, et al.
Publicado: (2023)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
por: Lu, Mong-Liang, et al.
Publicado: (2013)

Olanzapine Induced Hyponatraemia
por: Dudeja, Sonia J, et al.
Publicado: (2010)

Olanzapine-Induced Neutropenia
por: Malhotra, Kirti, et al.
Publicado: (2015)

Olanzapine-induced Psoriasis
por: Chepure, Ashish Hanmantrao, et al.
Publicado: (2017)

Seizure associated with olanzapine
por: Uvais, N. A., et al.
Publicado: (2018)

Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study
por: Ascher-Svanum, Haya, et al.
Publicado: (2013)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
por: Anand, Ernie, et al.
Publicado: (2015)

Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study
por: Rikhari, Praveen, et al.
Publicado: (2022)

T35. A PHASE 3, MULTICENTER STUDY TO ASSESS THE 1-YEAR SAFETY AND TOLERABILITY OF A COMBINATION OF OLANZAPINE AND SAMIDORPHAN IN PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM THE ENLIGHTEN-2-EXTENSION
Publicado: (2020)

Hyperglycemia associated with olanzapine treatment
por: Kumar, P. N. Suresh, et al.
Publicado: (2011)

Olanzapine induced tardive dystonia
por: Aggarwal, Ashish, et al.
Publicado: (2008)

Treatment of Delusional Infestation with Olanzapine
por: Kansal, Naveen Kumar, et al.
Publicado: (2012)

Characterization of Olanzapine-Solid Dispersions
por: Krishnamoorthy, Venkateskumar, et al.
Publicado: (2011)

Olanzapine-induced Orthostatic Hypotension
por: Jana, Amlan Kusum, et al.
Publicado: (2015)

Olanzapine-induced eosinophilic pleuritis
por: Evison, Matthew, et al.
Publicado: (2014)

Emphysematous pancreatitis predisposed by Olanzapine
por: Samanta, Sukhen, et al.
Publicado: (2014)

Olanzapine-induced Skin Eruptions
por: Chawla, Nishtha, et al.
Publicado: (2017)

Caution with olanzapine use in dementia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9qh6cbs15l7vcqdqf8cgcimbpv